Takeda Taps AI Startup Iambic In $1.7 Billion+ Deal To Speed Up Drug Discovery

AI startup Iambic on Monday announced a multi-year technology and discovery collaboration agreement with Takeda Pharmaceutical Company Limited (NYSE:TAK) .The Japanese drug maker will use Iambic's AI drug discovery models to advance a select set of high-priority small molecule programs, initially in Takeda's oncology, gastrointestinal, and inflammation therapeutic areas.Through the agreement, Takeda will also gain access to NeuralPLexer, Iambic's model for predicting protein-ligand complexes.Based in San Di ...